USA flag logo/image

An Official Website of the United States Government

Repair of boney defects by human stem cells

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93469
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AR056893
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NEOSTEM, INC.
420 LEXINGTON AVE SUITE 350 NEW YORK, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Repair of boney defects by human stem cells
Agency: HHS
Contract: 1R43AR056893-01A1
Award Amount: $108,746.00
 

Abstract:

DESCRIPTION (provided by applicant): In alignment with Healthy People 2010 (Arthritis/Osteoporosis) and research objectives established by the NIAMS, the overall goal of this study is to prevent illness and disability related to arthritis and osteoporosis. This study will develop a marrow population of mesenchymal cells (MSCs) that are very small and have embryonic-like properties (VSEL cells). This study will develop MSCs for true regenerative medicine. We hypothesize that human VSEL cells represent true M SC cells that can be utilized for osseous regeneration - and ultimately for the treatment of osteoporosis. The aim of this study is to test in vivo the capacity of human VSEL cells to form bone in an animal model. The goals and objectives of this study are closely aligned with the official NIH position regarding stem cell research: to examine stem cells as a renewable source of replacement cells to treat diseases, conditions, and disabilities. PUBLIC HEALTH RELEVANCE: NeoStem will conduct research on stem cells and explore their enormous promise to produce breakthrough therapies and cures. The study will investigate the effect of a marrow population of mesenchymal cells (MSCs) that are very small and have embryonic-like properties (VSEL cells) that can be u tilized for bone regeneration - and ultimately for the treatment of osteoporosis. This study will test in vivo the capacity of human VSEL cells to form bone in an animal model and regenerate a critical sized boney defect.

Principal Investigator:

Denis O. Rodgerson
5105217392
SPYGLASS20@HOTMAIL.COM

Business Contact:

Denis Rodgerson
Small Business Information at Submission:

NEOSTEM, INC.
420 LEXINGTON AVE SUITE 450 NEW YORK, NY 10170

EIN/Tax ID: 122234356
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No